Oncotarget

Reviews:

Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis

Guanying Luo, Yunzhao Hu, Zhiqiao Zhang _, Peng Wang, Zhaowen Luo, Jinxin Lin, Canchang Cheng and You Yang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:50273-50283. https://doi.org/10.18632/oncotarget.17305

Metrics: PDF 955 views  |   HTML 1815 views  |   ?  


Abstract

Guanying Luo1,2,*, Yunzhao Hu1,2,*, Zhiqiao Zhang1,2, Peng Wang1, Zhaowen Luo2, Jinxin Lin2, Canchang Cheng1,2 and You Yang1,2

1 Department of Infectious Diseases, The First People’s Hospital of Shunde, Shunde, Guangdong, China

2 Department of Internal Medicine, The Chencun Affiliated Hospital of First People’s Hospital of Shunde, Shunde, Guangdong, China

* These authors have contributed equally to this study and were co-first authors

Correspondence to:

Zhiqiao Zhang, email:

Keywords: gastric cancer; ki-67;meta-analysis; prognostic value

Received: August 01, 2016 Accepted: February 06, 2017 Published: April 20, 2017

Abstract

Background: The prognostic value and clinicopathologic significance of Ki-67 expression in gastric cancer patients was controversial. This meta-analysis was performed to clarify the prognostic value and clinicopathologic significance of Ki-67 expression in gastric cancer patients.

Materials and Methods: Several electronic databases were searched for eligible studies. The pooled odds ratio (OR), hazard ratios (HR) and 95% confidence interval(CI) were calculated to explore the prognostic value and clinicopathologic significance of Ki-67 expression for disease free survival and overall survival.

Results: Totally 5600 gastric cancer patients from 29 studies were included in this study. High Ki-67 expression was significantly related with Lauren’s classification (OR = 1.70; P = 0.001; 95%CI: 1.40-2.06) and tumor size(OR = 1.54; P = 0.006; 95%CI: 1.14-2.09). However, high Ki-67 expression was not significantly associated with lymph node metastasis (OR = 1.37; P = 0.138; 95% CI: 0.90-2.08) , tumor stage (OR = 1.31; P = 0.296; 95% CI: 0.79-2.16) and tumor differentiation (OR = 1.03; P = 0.839; 95% CI: 0.78-1.35). The pooled HRs were 1.87(P = 0.001; 95% CI 1.30-2.69) for disease free survival and 1.23(P = 0.005; 95% CI 1.06-1.42) for overall survival.

Conclusions: High Ki-67 expression may serve as a predictive biomarker for poor prognosis in gastric cancer patients. Stratification by Ki-67 expression may be a consideration for selection of therapeutic regimen and integrated managements.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17305